MedTrace Logo

Continuous Glucose Monitoring System Use in Pediatric Patients with Diabetes

NCT06570551 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2024-09-26

No results posted yet for this study

Summary

To verify and evaluate the efficacy and safety of i3 CGM system manufactured by Changsha Sinocare Inc. for continuous or regular monitoring of interstitial fluid glucose level in pediatric patients with diabetes.

Conditions

Interventions

DEVICE

i3 CGM(continuous glucose monitor)

The i3 CGM consists of a Sensor Pack (including probe, iCGM-S3), a Transmitter Pack (iCGM-t3), and an application (iCGM-APP (released version: V02)).application (i3 CGM App). The user can view their glucose data on the i3 CGM App running on a compatible mobile device.

Sponsors & Collaborators

  • Sinocare

    lead INDUSTRY

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2024-08-21
Completion
2024-08-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06570551 on ClinicalTrials.gov